2. Search Result
Search Result
Results for "

lysosomal hydrolase

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Recombinant Proteins

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116815
    Lalistat 1
    2 Publications Verification

    		 Beta-lactamase Bacterial Infection Neurological Disease
    Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .
    Lalistat 1
  • HY-113489
    14,15-Epoxyeicosatrienoic acid

    14,15-EET

    		 Endogenous Metabolite Cardiovascular Disease Neurological Disease
    14,15-Epoxyeicosatrienoic acid (14,15-EET) is a metabolite of Arachidonic acid (HY-109590). 14,15-Epoxyeicosatrienoic acid is a potent inhibitor of in vivo platelet aggregation. 14,15-Epoxyeicosatrienoic acid facilitates astrocytic Aβ clearance. 14,15-Epoxyeicosatrienoic acid can be used for Alzheimer's Disease research .
    14,15-Epoxyeicosatrienoic acid
  • HY-112487
    Sandoz 58-035

    		Acyltransferase Metabolic Disease
    Sandoz 58-035 is a selective acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor. Sandoz 58-035 inhibits this enzyme in intact cells and isolated microsomal fractions. Sandoz 58-035 blocks the esterification of exogenous vesicle-derived cholesterol and the incorporation of oleic acid into cellular cholesterol esters, reducing the formation and accumulation of cholesterol esters. Sandoz 58-035 causes a slight increase in cellular free cholesterol, and at high concentrations, it also causes a slight reduction in overall cellular protein synthesis. Sandoz 58-035 can be used in studies related to cellular cholesterol regulation .
    Sandoz 58-035
  • HY-101457
    JZP-430

    		MAGL Metabolic Disease
    JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .
    JZP-430
  • HY-114043
    NCGC00092410

    		Glycosidase Metabolic Disease
    NCGC00092410 is a potent, selective, and nonsugar glucocerebrosidase (GC) inhibitor, with an IC50 of 31 nM. NCGC00092410 shows no activity against the related hydrolases at concentrations up to 77 μM. NCGC00092410, a GC chaperone, and increases the activity and lysosomal localization of glucocerebrosidase in mutant cell lines. NCGC00092410 can be used for the research of Gaucher disease .
    NCGC00092410
  • HY-W698964
    2′-Hydroxy-5′-nitrohexadecanamide

    		Biochemical Assay Reagents Metabolic Disease
    2′-Hydroxy-5′-nitrohexadecanamide is a lysosomal hydrolase inhibitor and is a lipid containing pentadecanoic acid and a terminal nitrophenol in its structure. 2′-Hydroxy-5′-nitrohexadecanamide can cause intracellular lipid accumulation by inhibiting lysosomal hydrolase activity. Additionally, 2′-Hydroxy-5′-nitrohexadecanamide can be used to synthesize chromogenic substrates for measuring sphingolipase activity .
    2′-Hydroxy-5′-nitrohexadecanamide
  • HY-183907
    Cicletanine

    		Calcium Channel Cardiovascular Disease
    Cicletanine is a voltage-dependent Ca 2+ channel inhibitor. Cicletanine inhibits α-adrenoceptor-mediated Ca 2+ release pathway, and shows vasodilatory effects on isolated vascular smooth muscle. Cicletanine directly stimulates lysosomal and cytoplasmic cholesteryl ester hydrolase activity. Cicletanine can be used for the research of hypertension .
    Cicletanine
  • HY-182938
    Autophagy activator-2

    		Autophagy Metabolic Disease
    Autophagy activator-2 is a potent autophagy activator with EC50 values of 14.33 μM. Autophagy activator-2 acts as a proteostasis modulator and small-molecule chaperone that upregulates I1061T mutant NPC1 expression and facilitates cholesterol efflux. Autophagy activator-2 reduces lysosomal hydrolase levels. Autophagy activator-2 can be used for the study of Niemann-Pick Type C disease .
    Autophagy activator-2
  • HY-101457R
    JZP-430 (Standard)

    		MAGL Reference Standards Metabolic Disease
    JZP-430 (Standard) is the analytical standard of JZP-430 (HY-101457). This product is intended for research and analytical applications. JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .
    JZP-430 (Standard)
  • HY-P2858H
    β-Mannosidase, Streptomyces coelicolor

    		Biochemical Assay Reagents Others
    β-Mannosidase, Streptomyces coelicolor (EC 3.2.1.25) catalyses the following chemical reaction:Hydrolysis of terminal, non-reducing beta-D-mannose residues in beta-D-mannosides. This gene encodes a member of the glycosyl hydrolase 2 family. The encoded protein localizes to the lysosome where it is the final exoglycosidase in the pathway for N-linked glycoprotein oligosaccharide catabolism. Mutations in this gene are associated with beta-mannosidosis, a lysosomal storage disease that has a wide spectrum of neurological involvement.
    β-Mannosidase, Streptomyces coelicolor

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: